A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Status:
Completed
Trial end date:
2012-05-16
Target enrollment:
Participant gender:
Summary
In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in
patients with active rheumatoid arthritis who have had an inadequate response to
methotrexate. Patients will receive MabThera (1000mg iv infusion) on days 1 and 15, and
background methotrexate (10-25mg po or sc weekly). After the initial study period of 24
weeks, eligible patients may receive up to 3 re-treatments with MabThera. The anticipated
time on study treatment is 1-2 years and target sample size is <50